OA11419A - HIV-1tat, or derivatives thereof for prophylactic and therapeutic vaccination. - Google Patents

HIV-1tat, or derivatives thereof for prophylactic and therapeutic vaccination. Download PDF

Info

Publication number: OA11419A
Authority: OA; OAPI
Prior art keywords: tat; dna; aids; pro; seq
Prior art date: 1997-12-01

Application number

OA1200000159A

Other languages

English (en)

Inventor

Barhara Ensoli

Original Assignee

Ist Superiore Sanita

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-01

Filing date

2000-05-30

Publication date

2004-04-21

2000-05-30 Application filed by Ist Superiore Sanita filed Critical Ist Superiore Sanita

2004-04-21 Publication of OA11419A publication Critical patent/OA11419A/en

Links

230000000069 prophylactic effect Effects 0.000 title claims abstract description 12
238000002255 vaccination Methods 0.000 title claims description 21
230000001225 therapeutic effect Effects 0.000 title claims description 14
108090000623 proteins and genes Proteins 0.000 claims abstract description 134
229960005486 vaccine Drugs 0.000 claims abstract description 89
208000030507 AIDS Diseases 0.000 claims abstract description 57
108090000695 Cytokines Proteins 0.000 claims abstract description 51
102000004127 Cytokines Human genes 0.000 claims abstract description 50
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 42
241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 40
239000013612 plasmid Substances 0.000 claims abstract description 32
108090000172 Interleukin-15 Proteins 0.000 claims abstract description 30
102000003812 Interleukin-15 Human genes 0.000 claims abstract description 29
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 27
206010028980 Neoplasm Diseases 0.000 claims abstract description 26
208000031886 HIV Infections Diseases 0.000 claims abstract description 18
208000011580 syndromic disease Diseases 0.000 claims abstract description 16
208000037357 HIV infectious disease Diseases 0.000 claims abstract description 14
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims abstract description 14
208000024891 symptom Diseases 0.000 claims abstract description 13
108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 11
102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 11
238000011161 development Methods 0.000 claims abstract description 9
239000000203 mixture Substances 0.000 claims abstract description 7
241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 6
108020001507 fusion proteins Proteins 0.000 claims abstract description 6
102000037865 fusion proteins Human genes 0.000 claims abstract description 6
229940021747 therapeutic vaccine Drugs 0.000 claims abstract description 5
101710149951 Protein Tat Proteins 0.000 claims description 547
210000004027 cell Anatomy 0.000 claims description 258
230000003612 virological effect Effects 0.000 claims description 100
108020004414 DNA Proteins 0.000 claims description 96
102000004169 proteins and genes Human genes 0.000 claims description 84
230000000694 effects Effects 0.000 claims description 67
239000013598 vector Substances 0.000 claims description 56
238000002649 immunization Methods 0.000 claims description 51
230000003053 immunization Effects 0.000 claims description 50
241000700605 Viruses Species 0.000 claims description 47
210000004443 dendritic cell Anatomy 0.000 claims description 40
230000028993 immune response Effects 0.000 claims description 34
229940037003 alum Drugs 0.000 claims description 33
239000000427 antigen Substances 0.000 claims description 33
108091007433 antigens Proteins 0.000 claims description 33
102000036639 antigens Human genes 0.000 claims description 33
239000002671 adjuvant Substances 0.000 claims description 31
230000014509 gene expression Effects 0.000 claims description 31
229960000814 tetanus toxoid Drugs 0.000 claims description 31
239000011324 bead Substances 0.000 claims description 26
230000002441 reversible effect Effects 0.000 claims description 21
238000004519 manufacturing process Methods 0.000 claims description 20
150000001413 amino acids Chemical group 0.000 claims description 18
208000007766 Kaposi sarcoma Diseases 0.000 claims description 17
108010041986 DNA Vaccines Proteins 0.000 claims description 14
229940021995 DNA vaccine Drugs 0.000 claims description 14
241000894006 Bacteria Species 0.000 claims description 13
108700004027 tat Genes Proteins 0.000 claims description 11
101150098170 tat gene Proteins 0.000 claims description 10
101100256737 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) hlm-1 gene Proteins 0.000 claims description 9
230000007416 antiviral immune response Effects 0.000 claims description 9
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
230000009885 systemic effect Effects 0.000 claims description 9
101710177291 Gag polyprotein Proteins 0.000 claims description 8
239000012634 fragment Substances 0.000 claims description 8
230000001939 inductive effect Effects 0.000 claims description 8
239000002105 nanoparticle Substances 0.000 claims description 8
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 7
241000186660 Lactobacillus Species 0.000 claims description 7
108700004026 gag Genes Proteins 0.000 claims description 7
210000004877 mucosa Anatomy 0.000 claims description 7
229940039696 lactobacillus Drugs 0.000 claims description 6
210000005259 peripheral blood Anatomy 0.000 claims description 6
239000011886 peripheral blood Substances 0.000 claims description 6
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 5
230000003213 activating effect Effects 0.000 claims description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
238000011282 treatment Methods 0.000 claims description 5
101710125418 Major capsid protein Proteins 0.000 claims description 4
101710150344 Protein Rev Proteins 0.000 claims description 4
239000012530 fluid Substances 0.000 claims description 4
230000005298 paramagnetic effect Effects 0.000 claims description 4
108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
239000003112 inhibitor Substances 0.000 claims description 3
238000007918 intramuscular administration Methods 0.000 claims description 3
230000005012 migration Effects 0.000 claims description 3
238000013508 migration Methods 0.000 claims description 3
108700004028 nef Genes Proteins 0.000 claims description 3
229940023041 peptide vaccine Drugs 0.000 claims description 3
230000009545 invasion Effects 0.000 claims description 2
241000714195 Aids-associated retrovirus Species 0.000 claims 32
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 10
RMJZWERKFFNNNS-XGEHTFHBSA-N Pro-Thr-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O RMJZWERKFFNNNS-XGEHTFHBSA-N 0.000 claims 7
108010029539 arginyl-prolyl-proline Proteins 0.000 claims 7
XPSGESXVBSQZPL-SRVKXCTJSA-N Arg-Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XPSGESXVBSQZPL-SRVKXCTJSA-N 0.000 claims 6
KGIHMGPYGXBYJJ-SRVKXCTJSA-N Cys-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CS KGIHMGPYGXBYJJ-SRVKXCTJSA-N 0.000 claims 6
BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 claims 6
SRWWRLKBEJZFPW-IHRRRGAJSA-N Val-Cys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N SRWWRLKBEJZFPW-IHRRRGAJSA-N 0.000 claims 6
VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 claims 6
239000013604 expression vector Substances 0.000 claims 6
UQJUGHFKNKGHFQ-VZFHVOOUSA-N Ala-Cys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UQJUGHFKNKGHFQ-VZFHVOOUSA-N 0.000 claims 5
OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 claims 5
BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 claims 5
CZIXHXIJJZLYRJ-SRVKXCTJSA-N Asn-Cys-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CZIXHXIJJZLYRJ-SRVKXCTJSA-N 0.000 claims 5
QCBYAHHNOHBXIH-UWVGGRQHSA-N His-Pro-Gly Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)C1=CN=CN1 QCBYAHHNOHBXIH-UWVGGRQHSA-N 0.000 claims 5
OGAZPKJHHZPYFK-GARJFASQSA-N Met-Glu-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N OGAZPKJHHZPYFK-GARJFASQSA-N 0.000 claims 5
WFIVLLFYUZZWOD-RHYQMDGZSA-N Pro-Lys-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WFIVLLFYUZZWOD-RHYQMDGZSA-N 0.000 claims 5
FYXCBXDAMPEHIQ-FHWLQOOXSA-N Pro-Trp-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCCCN)C(=O)O FYXCBXDAMPEHIQ-FHWLQOOXSA-N 0.000 claims 5
HQTKVSCNCDLXSX-BQBZGAKWSA-N Ser-Arg-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O HQTKVSCNCDLXSX-BQBZGAKWSA-N 0.000 claims 5
DDNIHOWRDOXXPF-NGZCFLSTSA-N Val-Asp-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N DDNIHOWRDOXXPF-NGZCFLSTSA-N 0.000 claims 5
108010053725 prolylvaline Proteins 0.000 claims 5
MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 claims 4
MAJYPBAJPNUFPV-BQBZGAKWSA-N His-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MAJYPBAJPNUFPV-BQBZGAKWSA-N 0.000 claims 4
WLRJHVNFGAOYPS-HJPIBITLSA-N Ile-Ser-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N WLRJHVNFGAOYPS-HJPIBITLSA-N 0.000 claims 4
QGXQHJQPAPMACW-PPCPHDFISA-N Ile-Thr-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)O)N QGXQHJQPAPMACW-PPCPHDFISA-N 0.000 claims 4
XQPHBAKJJJZOBX-SRVKXCTJSA-N Pro-Lys-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O XQPHBAKJJJZOBX-SRVKXCTJSA-N 0.000 claims 4
108010004073 cysteinylcysteine Proteins 0.000 claims 4
230000003190 augmentative effect Effects 0.000 claims 3
108010061238 threonyl-glycine Proteins 0.000 claims 3
RVMXMLSYBTXCAV-VEVYYDQMSA-N Asp-Pro-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMXMLSYBTXCAV-VEVYYDQMSA-N 0.000 claims 2
QJUDRFBUWAGUSG-SRVKXCTJSA-N Cys-Cys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)N QJUDRFBUWAGUSG-SRVKXCTJSA-N 0.000 claims 2
KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 claims 2
DCHQYSOGURGJST-FJXKBIBVSA-N Pro-Thr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O DCHQYSOGURGJST-FJXKBIBVSA-N 0.000 claims 2
FLONGDPORFIVQW-XGEHTFHBSA-N Ser-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FLONGDPORFIVQW-XGEHTFHBSA-N 0.000 claims 2
WXVIGTAUZBUDPZ-DTLFHODZSA-N Thr-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 WXVIGTAUZBUDPZ-DTLFHODZSA-N 0.000 claims 2
108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims 2
238000002560 therapeutic procedure Methods 0.000 claims 2
OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 claims 1
VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 claims 1
YCYXHLZRUSJITQ-SRVKXCTJSA-N Arg-Pro-Pro Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 YCYXHLZRUSJITQ-SRVKXCTJSA-N 0.000 claims 1
ZKAOJVJQGVUIIU-GUBZILKMSA-N Asp-Pro-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ZKAOJVJQGVUIIU-GUBZILKMSA-N 0.000 claims 1
MFMDKTLJCUBQIC-MXAVVETBSA-N Cys-Phe-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O MFMDKTLJCUBQIC-MXAVVETBSA-N 0.000 claims 1
NNQDRRUXFJYCCJ-NHCYSSNCSA-N Glu-Pro-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O NNQDRRUXFJYCCJ-NHCYSSNCSA-N 0.000 claims 1
GAAHQHNCMIAYEX-UWVGGRQHSA-N Gly-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN GAAHQHNCMIAYEX-UWVGGRQHSA-N 0.000 claims 1
NURNJECQNNCRBK-FLBSBUHZSA-N Ile-Thr-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NURNJECQNNCRBK-FLBSBUHZSA-N 0.000 claims 1
OGUUKPXUTHOIAV-SDDRHHMPSA-N Leu-Glu-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N OGUUKPXUTHOIAV-SDDRHHMPSA-N 0.000 claims 1
CCQLQKZTXZBXTN-NHCYSSNCSA-N Leu-Gly-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O CCQLQKZTXZBXTN-NHCYSSNCSA-N 0.000 claims 1
GNLJXWBNLAIPEP-MELADBBJSA-N Lys-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCCCN)N)C(=O)O GNLJXWBNLAIPEP-MELADBBJSA-N 0.000 claims 1
102000008300 Mutant Proteins Human genes 0.000 claims 1
108010021466 Mutant Proteins Proteins 0.000 claims 1
RVQDZELMXZRSSI-IUCAKERBSA-N Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 RVQDZELMXZRSSI-IUCAKERBSA-N 0.000 claims 1
101710192141 Protein Nef Proteins 0.000 claims 1
YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 claims 1
FHXGMDRKJHKLKW-QWRGUYRKSA-N Ser-Tyr-Gly Chemical compound OC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 FHXGMDRKJHKLKW-QWRGUYRKSA-N 0.000 claims 1
NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 claims 1
PMDWYLVWHRTJIW-STQMWFEESA-N Tyr-Gly-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PMDWYLVWHRTJIW-STQMWFEESA-N 0.000 claims 1
239000002870 angiogenesis inducing agent Substances 0.000 claims 1
108010062796 arginyllysine Proteins 0.000 claims 1
239000000969 carrier Substances 0.000 claims 1
108010092114 histidylphenylalanine Proteins 0.000 claims 1
230000005291 magnetic effect Effects 0.000 claims 1
230000002163 immunogen Effects 0.000 abstract description 20
108010067390 Viral Proteins Proteins 0.000 abstract description 10
229940021993 prophylactic vaccine Drugs 0.000 abstract description 3
241000282693 Cercopithecidae Species 0.000 description 285
208000015181 infectious disease Diseases 0.000 description 75
235000018102 proteins Nutrition 0.000 description 74
101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 58
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 58
238000004458 analytical method Methods 0.000 description 49
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 40
238000012360 testing method Methods 0.000 description 40
230000000840 anti-viral effect Effects 0.000 description 38
238000003556 assay Methods 0.000 description 36
230000004044 response Effects 0.000 description 35
238000002474 experimental method Methods 0.000 description 32
210000001744 T-lymphocyte Anatomy 0.000 description 31
239000002609 medium Substances 0.000 description 31
238000000034 method Methods 0.000 description 31
101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 30
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 30
241000282414 Homo sapiens Species 0.000 description 29
210000004698 lymphocyte Anatomy 0.000 description 29
230000005764 inhibitory process Effects 0.000 description 28
238000002965 ELISA Methods 0.000 description 22
238000010790 dilution Methods 0.000 description 21
239000012895 dilution Substances 0.000 description 21
238000011081 inoculation Methods 0.000 description 20
230000001404 mediated effect Effects 0.000 description 20
210000004369 blood Anatomy 0.000 description 19
239000008280 blood Substances 0.000 description 19
230000001413 cellular effect Effects 0.000 description 19
239000006228 supernatant Substances 0.000 description 19
108010002350 Interleukin-2 Proteins 0.000 description 18
239000002077 nanosphere Substances 0.000 description 18
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 15
108010055166 Chemokine CCL5 Proteins 0.000 description 13
102000001327 Chemokine CCL5 Human genes 0.000 description 13
241001465754 Metazoa Species 0.000 description 13
208000037581 Persistent Infection Diseases 0.000 description 13
239000000872 buffer Substances 0.000 description 13
241000282553 Macaca Species 0.000 description 12
241000699670 Mus sp. Species 0.000 description 12
108700012920 TNF Proteins 0.000 description 12
238000007792 addition Methods 0.000 description 12
239000000047 product Substances 0.000 description 12
102000005962 receptors Human genes 0.000 description 12
108020003175 receptors Proteins 0.000 description 12
230000000638 stimulation Effects 0.000 description 12
102000004388 Interleukin-4 Human genes 0.000 description 11
108090000978 Interleukin-4 Proteins 0.000 description 11
230000001154 acute effect Effects 0.000 description 11
235000001014 amino acid Nutrition 0.000 description 11
238000011534 incubation Methods 0.000 description 11
241000700588 Human alphaherpesvirus 1 Species 0.000 description 10
241000282567 Macaca fascicularis Species 0.000 description 10
229940024606 amino acid Drugs 0.000 description 10
239000001963 growth medium Substances 0.000 description 10
230000006698 induction Effects 0.000 description 10
230000002458 infectious effect Effects 0.000 description 10
102000006495 integrins Human genes 0.000 description 10
108010044426 integrins Proteins 0.000 description 10
238000006467 substitution reaction Methods 0.000 description 10
210000000612 antigen-presenting cell Anatomy 0.000 description 9
238000012512 characterization method Methods 0.000 description 9
201000010099 disease Diseases 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
239000012737 fresh medium Substances 0.000 description 9
238000000338 in vitro Methods 0.000 description 9
101710147327 Calcineurin B homologous protein 1 Proteins 0.000 description 8
101710205625 Capsid protein p24 Proteins 0.000 description 8
102000019034 Chemokines Human genes 0.000 description 8
108010012236 Chemokines Proteins 0.000 description 8
229920001917 Ficoll Polymers 0.000 description 8
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 8
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 8
102100034353 Integrase Human genes 0.000 description 8
101710177166 Phosphoprotein Proteins 0.000 description 8
239000012980 RPMI-1640 medium Substances 0.000 description 8
101710149279 Small delta antigen Proteins 0.000 description 8
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 8
102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 8
108010031318 Vitronectin Proteins 0.000 description 8
102100035140 Vitronectin Human genes 0.000 description 8
230000004071 biological effect Effects 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
230000001472 cytotoxic effect Effects 0.000 description 8
238000002955 isolation Methods 0.000 description 8
210000002540 macrophage Anatomy 0.000 description 8
238000011533 pre-incubation Methods 0.000 description 8
230000001566 pro-viral effect Effects 0.000 description 8
230000001681 protective effect Effects 0.000 description 8
238000000746 purification Methods 0.000 description 8
238000004448 titration Methods 0.000 description 8
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 7
230000002378 acidificating effect Effects 0.000 description 7
230000005540 biological transmission Effects 0.000 description 7
230000000875 corresponding effect Effects 0.000 description 7
239000012636 effector Substances 0.000 description 7
230000006870 function Effects 0.000 description 7
238000013507 mapping Methods 0.000 description 7
239000000178 monomer Substances 0.000 description 7
238000003752 polymerase chain reaction Methods 0.000 description 7
239000000126 substance Substances 0.000 description 7
230000009385 viral infection Effects 0.000 description 7
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
208000036142 Viral infection Diseases 0.000 description 6
230000036436 anti-hiv Effects 0.000 description 6
230000005875 antibody response Effects 0.000 description 6
239000012228 culture supernatant Substances 0.000 description 6
229960002897 heparin Drugs 0.000 description 6
229920000669 heparin Polymers 0.000 description 6
230000036039 immunity Effects 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
239000000523 sample Substances 0.000 description 6
238000013207 serial dilution Methods 0.000 description 6
-1 CDU Proteins 0.000 description 5
206010061818 Disease progression Diseases 0.000 description 5
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 5
241000194026 Streptococcus gordonii Species 0.000 description 5
108700005077 Viral Genes Proteins 0.000 description 5
230000000735 allogeneic effect Effects 0.000 description 5
230000001580 bacterial effect Effects 0.000 description 5
238000010367 cloning Methods 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
230000005750 disease progression Effects 0.000 description 5
230000004927 fusion Effects 0.000 description 5
210000000987 immune system Anatomy 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
230000002757 inflammatory effect Effects 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
239000002054 inoculum Substances 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
230000003472 neutralizing effect Effects 0.000 description 5
231100000252 nontoxic Toxicity 0.000 description 5
230000003000 nontoxic effect Effects 0.000 description 5
238000001890 transfection Methods 0.000 description 5
238000005406 washing Methods 0.000 description 5
102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 4
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 4
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
206010015150 Erythema Diseases 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
241000282412 Homo Species 0.000 description 4
101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 4
239000004472 Lysine Substances 0.000 description 4
108700008625 Reporter Genes Proteins 0.000 description 4
230000004913 activation Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
235000018417 cysteine Nutrition 0.000 description 4
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
239000003814 drug Substances 0.000 description 4
231100000321 erythema Toxicity 0.000 description 4
229960000900 human factor viii Drugs 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
238000010348 incorporation Methods 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
230000003993 interaction Effects 0.000 description 4
210000000265 leukocyte Anatomy 0.000 description 4
210000001165 lymph node Anatomy 0.000 description 4
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
210000001616 monocyte Anatomy 0.000 description 4
230000037361 pathway Effects 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000002269 spontaneous effect Effects 0.000 description 4
229940104230 thymidine Drugs 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
241000283690 Bos taurus Species 0.000 description 3
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
108020004635 Complementary DNA Proteins 0.000 description 3
208000006313 Delayed Hypersensitivity Diseases 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
229920003134 Eudragit® polymer Polymers 0.000 description 3
241000282326 Felis catus Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
108060003951 Immunoglobulin Proteins 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
206010029113 Neovascularisation Diseases 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
102100040247 Tumor necrosis factor Human genes 0.000 description 3
108020005202 Viral DNA Proteins 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
230000036755 cellular response Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
210000000805 cytoplasm Anatomy 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003792 electrolyte Substances 0.000 description 3
238000007824 enzymatic assay Methods 0.000 description 3
238000000799 fluorescence microscopy Methods 0.000 description 3
101150098622 gag gene Proteins 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
102000018358 immunoglobulin Human genes 0.000 description 3
229940072221 immunoglobulins Drugs 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
239000012139 lysis buffer Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000035772 mutation Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000013600 plasmid vector Substances 0.000 description 3
238000006116 polymerization reaction Methods 0.000 description 3
201000008752 progressive muscular atrophy Diseases 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
241000894007 species Species 0.000 description 3
JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
208000027930 type IV hypersensitivity disease Diseases 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
230000002792 vascular Effects 0.000 description 3
LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 2
238000010600 3H thymidine incorporation assay Methods 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
101150013553 CD40 gene Proteins 0.000 description 2
101100152433 Caenorhabditis elegans tat-1 gene Proteins 0.000 description 2
101100480622 Caenorhabditis elegans tat-5 gene Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108700024394 Exon Proteins 0.000 description 2
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
102100037362 Fibronectin Human genes 0.000 description 2
108010067306 Fibronectins Proteins 0.000 description 2
241000192125 Firmicutes Species 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
229940033330 HIV vaccine Drugs 0.000 description 2
102000006354 HLA-DR Antigens Human genes 0.000 description 2
108010058597 HLA-DR Antigens Proteins 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 description 2
101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
208000029462 Immunodeficiency disease Diseases 0.000 description 2
206010062016 Immunosuppression Diseases 0.000 description 2
102100022337 Integrin alpha-V Human genes 0.000 description 2
102100025304 Integrin beta-1 Human genes 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
102000003814 Interleukin-10 Human genes 0.000 description 2
108090000174 Interleukin-10 Proteins 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
101000986989 Naja kaouthia Acidic phospholipase A2 CM-II Proteins 0.000 description 2
208000001388 Opportunistic Infections Diseases 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000024932 T cell mediated immunity Effects 0.000 description 2
102100025237 T-cell surface antigen CD2 Human genes 0.000 description 2
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
108010003533 Viral Envelope Proteins Proteins 0.000 description 2
108010052104 Viral Regulatory and Accessory Proteins Proteins 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
230000004075 alteration Effects 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
229960003150 bupivacaine Drugs 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
108091092356 cellular DNA Proteins 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000010276 construction Methods 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
230000016396 cytokine production Effects 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
230000007402 cytotoxic response Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000005755 formation reaction Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
230000002489 hematologic effect Effects 0.000 description 2
102000057593 human F8 Human genes 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
230000028996 humoral immune response Effects 0.000 description 2
230000008348 humoral response Effects 0.000 description 2
230000009610 hypersensitivity Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
230000016784 immunoglobulin production Effects 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000009533 lab test Methods 0.000 description 2
230000021633 leukocyte mediated immunity Effects 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000007108 local immune response Effects 0.000 description 2
230000004807 localization Effects 0.000 description 2
125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
238000005259 measurement Methods 0.000 description 2
210000004779 membrane envelope Anatomy 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
229960002216 methylparaben Drugs 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
150000003833 nucleoside derivatives Chemical class 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
238000007747 plating Methods 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
239000013641 positive control Substances 0.000 description 2
230000002516 postimmunization Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
229940023143 protein vaccine Drugs 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
230000006798 recombination Effects 0.000 description 2
238000005215 recombination Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
238000002976 reverse transcriptase assay Methods 0.000 description 2
238000003757 reverse transcription PCR Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
230000014599 transmission of virus Effects 0.000 description 2
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
210000003606 umbilical vein Anatomy 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
RVNZEJNWTUDQSC-JOCHJYFZSA-N (2r)-n-(6-aminohexyl)-1-tridecanoylpyrrolidine-2-carboxamide Chemical compound CCCCCCCCCCCCC(=O)N1CCC[C@@H]1C(=O)NCCCCCCN RVNZEJNWTUDQSC-JOCHJYFZSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
JCVDICFLPGDHAT-DJLDLDEBSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3,5-dimethylpyrimidine-2,4-dione Chemical compound O=C1N(C)C(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 JCVDICFLPGDHAT-DJLDLDEBSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
ACNUVXZPCIABEX-UHFFFAOYSA-N 3',6'-diaminospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(N)C=C1OC1=CC(N)=CC=C21 ACNUVXZPCIABEX-UHFFFAOYSA-N 0.000 description 1
VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
101100221153 Arabidopsis thaliana CNGC4 gene Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
101150054111 Aspg gene Proteins 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
241000779745 Backhousia myrtifolia Species 0.000 description 1
108700029181 Bacteria lipase activator Proteins 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
102000001902 CC Chemokines Human genes 0.000 description 1
108010040471 CC Chemokines Proteins 0.000 description 1
241000282461 Canis lupus Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
101150074155 DHFR gene Proteins 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
238000011238 DNA vaccination Methods 0.000 description 1
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
229910052693 Europium Inorganic materials 0.000 description 1
241000233866 Fungi Species 0.000 description 1
206010060891 General symptom Diseases 0.000 description 1
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
229920002971 Heparan sulfate Polymers 0.000 description 1
101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 description 1
241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 description 1
241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
241000341655 Human papillomavirus type 16 Species 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
102100022297 Integrin alpha-X Human genes 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
241000714177 Murine leukemia virus Species 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
102000007999 Nuclear Proteins Human genes 0.000 description 1
108010089610 Nuclear Proteins Proteins 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
101710132659 Protein M6 Proteins 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
108010073443 Ribi adjuvant Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
241000713311 Simian immunodeficiency virus Species 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 1
102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
206010064390 Tumour invasion Diseases 0.000 description 1
206010058874 Viraemia Diseases 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
210000005221 acidic domain Anatomy 0.000 description 1
230000000240 adjuvant effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002424 anti-apoptotic effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000008350 antigen-specific antibody response Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229960001714 calcium phosphate Drugs 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
244000309466 calf Species 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
230000009400 cancer invasion Effects 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
230000023385 chemokine (C-C motif) ligand 5 production Effects 0.000 description 1
230000014564 chemokine production Effects 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
239000011258 core-shell material Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
108010078428 env Gene Products Proteins 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229940047127 fiore Drugs 0.000 description 1
238000010230 functional analysis Methods 0.000 description 1
230000005021 gait Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000012010 growth Effects 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000002998 immunogenetic effect Effects 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003999 initiator Substances 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
230000019734 interleukin-12 production Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
210000000207 lymphocyte subset Anatomy 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
229940127554 medical product Drugs 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
108010032806 molgramostim Proteins 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
230000016379 mucosal immune response Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000004719 natural immunity Effects 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000002887 neurotoxic effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000030648 nucleus localization Effects 0.000 description 1
230000014207 opsonization Effects 0.000 description 1
229940126578 oral vaccine Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229960005030 other vaccine in atc Drugs 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
238000011809 primate model Methods 0.000 description 1
230000000861 pro-apoptotic effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000006318 protein oxidation Effects 0.000 description 1
230000005180 public health Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
238000010526 radical polymerization reaction Methods 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
238000003753 real-time PCR Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
230000004960 subcellular localization Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
208000010648 susceptibility to HIV infection Diseases 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
JDFUJAMTCCQARF-UHFFFAOYSA-N tatb Chemical compound NC1=C([N+]([O-])=O)C(N)=C([N+]([O-])=O)C(N)=C1[N+]([O-])=O JDFUJAMTCCQARF-UHFFFAOYSA-N 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000005945 translocation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229960004319 trichloroacetic acid Drugs 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000006648 viral gene expression Effects 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
230000001018 virulence Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16041—Use of virus, viral particle or viral elements as a vector
- C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Virology (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
AIDS & HIV (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

OA1200000159A 1997-12-01 2000-05-30 HIV-1tat, or derivatives thereof for prophylactic and therapeutic vaccination. OA11419A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT97RM000743A IT1297090B1 (it)	1997-12-01	1997-12-01	Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le

Publications (1)

Publication Number	Publication Date
OA11419A true OA11419A (en)	2004-04-21

Family

ID=11405378

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200000159A OA11419A (en)	1997-12-01	2000-05-30	HIV-1tat, or derivatives thereof for prophylactic and therapeutic vaccination.

Country Status (23)

Country	Link
US (2)	US7744896B1 (fr)
EP (2)	EP1698347A3 (fr)
JP (1)	JP2001524531A (fr)
CN (1)	CN1283121A (fr)
AP (1)	AP2000001828A0 (fr)
AT (1)	ATE374041T1 (fr)
AU (1)	AU762893B2 (fr)
BR (1)	BR9814725A (fr)
CA (1)	CA2311647C (fr)
CU (1)	CU20000126A7 (fr)
CY (1)	CY1107818T1 (fr)
DE (1)	DE69838486T2 (fr)
DK (1)	DK1035865T3 (fr)
EA (1)	EA004330B1 (fr)
ES (1)	ES2293700T3 (fr)
IL (1)	IL136372A0 (fr)
IT (1)	IT1297090B1 (fr)
NZ (1)	NZ505373A (fr)
OA (1)	OA11419A (fr)
PL (1)	PL341818A1 (fr)
PT (1)	PT1035865E (fr)
TR (1)	TR200001553T2 (fr)
WO (1)	WO1999027958A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20150359878A1 (en) *	2013-01-22	2015-12-17	Vaxxit Srl	Use of replication deficient hsv-1 as a vaccine vector for the deli vary of hiv-1 tat antigen

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1297090B1 (it)	1997-12-01	1999-08-03	Barbara Ensoli	Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
US20010008627A1 (en) *	1999-01-22	2001-07-19	Soll David R.	Hiv-encoded chemoattractant
CA2367692A1 (fr) *	1999-03-15	2000-09-21	Introgen Therapeutics, Inc.	Cellules dendritiques transduites avec un gene du soi de type sauvage suscitant des reponses immunitaires antitumorales puissantes
AU4082300A (en) *	1999-06-21	2001-01-09	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Hiv tat peptides and multiple peptide conjugate system
KR100379577B1 (ko) *	2000-07-26	2003-04-08	최수영	세포침투성 티에이티 - 인간 글루탐산 탈수소효소 융합단백질, 이 융합단백질을 코딩하는 재조합폴리뉴클레오타이드, 이 융합단백질의 발현벡터 및 이융합단백질을 세포 내로 도입하는 방법
NO314587B1 (no) *	2000-09-04	2003-04-14	Bionor Immuno As	HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
EP1279404A1 (fr) *	2001-07-26	2003-01-29	Istituto Superiore di Sanità	Utilisation de HIV-1 tat fragments ou dérivés pour activer des cellules présentatrices d'antigènes, pour délivrer des molécules cargo pour la vaccination ou pour le traitement d'autres maladies
CA2458995C (fr) *	2001-08-31	2013-04-30	Chiron Corporation	Polynucleotides codant des polypeptides de type b du vih antigeniques, polypeptides et leurs utilisations
AU2002358181A1 (en) *	2001-12-11	2003-07-09	Aventis Pasteur	Mutated hiv tat
FR2834717B1 (fr) *	2002-01-11	2004-12-10	Bio Merieux	Mutants de la proteine tat du virus vih-1
UA82998C2 (ru)	2002-05-16	2008-06-10	Бавариан Нордик А/С	Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті
WO2004028561A1 (fr) *	2002-09-30	2004-04-08	Yamanouchi Pharmaceutical Co., Ltd.	Procede d'induction de reponses immunitaires
EP1570051B1 (fr) *	2002-11-19	2009-10-28	The Trustees of The University of Pennsylvania	Genes hybrides et compositions comprenant rre et cte et utilisations de ceux-ci
AU2003292136A1 (en) *	2002-11-26	2004-06-18	Eurocine Ab	Vaccines against viruses with cationic substances as adjuvants
EP1575601B1 (fr)	2002-12-16	2015-07-01	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Virus de la vaccine recombinants exprimant il-15 et méthodes d'utilisation des dits virus
GB0323840D0 (en) *	2003-10-10	2003-11-12	Ist Superiore Sanita	Vaccines
US8507277B2 (en)	2003-10-24	2013-08-13	Gencia Corporation	Nonviral vectors for delivering polynucleotides
US20090123468A1 (en)	2003-10-24	2009-05-14	Gencia Corporation	Transducible polypeptides for modifying metabolism
US8062891B2 (en)	2003-10-24	2011-11-22	Gencia Corporation	Nonviral vectors for delivering polynucleotides to plants
CA2543257C (fr)	2003-10-24	2013-12-31	Gencia Corporation	Procedes et compositions permettant de distribuer des polynucleotides
US8133733B2 (en)	2003-10-24	2012-03-13	Gencia Corporation	Nonviral vectors for delivering polynucleotides to target tissues
GB2407501A (en) *	2003-11-03	2005-05-04	Ist Superiore Sanita	Nanoparticles for delivery of a pharmacologically active agent, comprising water insoluble (co)polymer core & hydrophilic acrylate-based (co)polymer shell
US7927580B2 (en)	2004-03-16	2011-04-19	Nanirx, Inc.	Tat-based immunomodulatory compositions and methods of their discovery and use
FR2868318B1 (fr) *	2004-04-01	2012-11-16	Commissariat Energie Atomique	Antigene tat stabilise et ses applications pour la vaccination anti-vih
TW200613554A (en) *	2004-06-17	2006-05-01	Wyeth Corp	Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
EP1888105A2 (fr)	2005-05-12	2008-02-20	Introgen Therapeutics, Inc.	Vaccins p53 permettant de traiter les cancers
AU2007284656A1 (en)	2006-08-14	2008-02-21	Thymon, L.L.C.	Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
GB0802224D0 (en) *	2008-02-06	2008-03-12	Inst Superiore Di Sanito	Process for the production of vaccine components
US9439922B2 (en) *	2008-05-14	2016-09-13	Jawaharlal Nehru Centre For Advanced Scientific Research	Tat DNA sequences, gene constructs, vaccine and processes thereof
EP2411043B1 (fr)	2009-03-23	2013-07-31	PIN Pharma, Inc.	Traitement du cancer avec des polypeptides immunostimulants dérivés de tat de vih
CN102153657A (zh) *	2011-01-18	2011-08-17	陕西师范大学	IL-24-Tat PTD融合蛋白及其构建方法和应用
WO2014151771A1 (fr) *	2013-03-14	2014-09-25	The J. David Gladstone Institutes	Compositions et procédés pour traiter une infection par un virus d'immunodéficience
CN105705164A (zh)	2013-10-04	2016-06-22	品诺制药公司	用于癌症治疗的免疫刺激性hiv tat衍生多肽
CN103936863B (zh) *	2014-04-23	2017-01-04	西安交通大学	一种调控stat3磷酸化的融合肽及其应用
CN104001155B (zh) *	2014-06-12	2016-04-13	中山大学	一种Tat蛋白及其制备方法和应用
EP2982693A1 (fr) *	2014-08-07	2016-02-10	Affimed Therapeutics AG	Domaine de liaison CD3
WO2018217897A1 (fr) *	2017-05-23	2018-11-29	David Weiner	Méthodes et compositions pour induire une réponse immunitaire
CN109943590B (zh) *	2019-04-18	2022-11-18	西南大学	一种复制缺陷型猪圆环病毒、其制备方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT83682B (en) *	1985-11-06	1988-12-05	Smithkline Beckman Corp	Process for the expression of an aids virus gene
US5670617A (en) *	1989-12-21	1997-09-23	Biogen Inc	Nucleic acid conjugates of tat-derived transport polypeptides
US5646120A (en) *	1990-10-24	1997-07-08	Allelix Biopharmaceuticals, Inc.	Peptide-based inhibitors of HIV replication
EP0491218A1 (fr) *	1990-12-17	1992-06-24	F. Hoffmann-La Roche Ag	Benzodiazépinones
US6107062A (en)	1992-07-30	2000-08-22	Inpax, Inc.	Antisense viruses and antisense-ribozyme viruses
WO1994015634A1 (fr)	1992-12-30	1994-07-21	Matthias Rath	Oligopeptide tat et rev utilises pour le traitement du vih
WO1995031999A1 (fr) *	1994-05-23	1995-11-30	Immunogiology Research Institute, Inc.	Compositions de proteines de transactivation du virus d'immunodeficience humaine
US6024965A (en) *	1996-10-18	2000-02-15	Erasums University Rotterdam	Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
IT1297090B1 (it)	1997-12-01	1999-08-03	Barbara Ensoli	Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
BR0107972A (pt) *	2000-01-31	2002-11-05	Smithkline Beecham Biologicals	Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano

1997
- 1997-12-01 IT IT97RM000743A patent/IT1297090B1/it active IP Right Grant
1998
- 1998-11-30 PT PT98966601T patent/PT1035865E/pt unknown
- 1998-11-30 EP EP05026908A patent/EP1698347A3/fr not_active Withdrawn
- 1998-11-30 WO PCT/EP1998/007721 patent/WO1999027958A2/fr not_active Ceased
- 1998-11-30 NZ NZ505373A patent/NZ505373A/en not_active IP Right Cessation
- 1998-11-30 JP JP2000522943A patent/JP2001524531A/ja active Pending
- 1998-11-30 TR TR2000/01553T patent/TR200001553T2/xx unknown
- 1998-11-30 EP EP98966601A patent/EP1035865B1/fr not_active Expired - Lifetime
- 1998-11-30 IL IL13637298A patent/IL136372A0/xx not_active IP Right Cessation
- 1998-11-30 EA EA200000596A patent/EA004330B1/ru not_active IP Right Cessation
- 1998-11-30 PL PL98341818A patent/PL341818A1/xx unknown
- 1998-11-30 ES ES98966601T patent/ES2293700T3/es not_active Expired - Lifetime
- 1998-11-30 DK DK98966601T patent/DK1035865T3/da active
- 1998-11-30 AT AT98966601T patent/ATE374041T1/de active
- 1998-11-30 AU AU24126/99A patent/AU762893B2/en not_active Ceased
- 1998-11-30 BR BR9814725-0A patent/BR9814725A/pt not_active IP Right Cessation
- 1998-11-30 DE DE69838486T patent/DE69838486T2/de not_active Expired - Lifetime
- 1998-11-30 AP APAP/P/2000/001828A patent/AP2000001828A0/en unknown
- 1998-11-30 CN CN98812496A patent/CN1283121A/zh active Pending
- 1998-11-30 CA CA2311647A patent/CA2311647C/fr not_active Expired - Fee Related
- 1998-11-30 US US09/555,534 patent/US7744896B1/en not_active Expired - Fee Related
2000
- 2000-05-30 OA OA1200000159A patent/OA11419A/en unknown
- 2000-05-31 CU CU20000126A patent/CU20000126A7/es unknown
2007
- 2007-11-29 CY CY20071101530T patent/CY1107818T1/el unknown
2009
- 2009-05-06 US US12/436,119 patent/US8197820B2/en not_active Expired - Fee Related

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20150359878A1 (en) *	2013-01-22	2015-12-17	Vaxxit Srl	Use of replication deficient hsv-1 as a vaccine vector for the deli vary of hiv-1 tat antigen

Also Published As

Publication number	Publication date
PT1035865E (pt)	2007-12-07
CA2311647A1 (fr)	1999-06-10
DE69838486T2 (de)	2008-06-26
AU2412699A (en)	1999-06-16
ES2293700T3 (es)	2008-03-16
AU762893B2 (en)	2003-07-10
JP2001524531A (ja)	2001-12-04
CY1107818T1 (el)	2013-06-19
IT1297090B1 (it)	1999-08-03
AP2000001828A0 (en)	2000-06-30
WO1999027958A2 (fr)	1999-06-10
WO1999027958A3 (fr)	1999-07-22
ITRM970743A1 (it)	1999-06-01
IL136372A0 (en)	2001-06-14
EP1698347A2 (fr)	2006-09-06
CN1283121A (zh)	2001-02-07
NZ505373A (en)	2003-07-25
CA2311647C (fr)	2013-03-19
CU20000126A7 (es)	2005-10-19
EA200000596A1 (ru)	2000-12-25
ATE374041T1 (de)	2007-10-15
US8197820B2 (en)	2012-06-12
EP1698347A3 (fr)	2006-12-20
BR9814725A (pt)	2000-10-03
EP1035865B1 (fr)	2007-09-26
US20100015087A1 (en)	2010-01-21
EA004330B1 (ru)	2004-04-29
PL341818A1 (en)	2001-05-07
TR200001553T2 (tr)	2000-11-21
WO1999027958A9 (fr)	1999-09-10
DE69838486D1 (de)	2007-11-08
EP1035865A2 (fr)	2000-09-20
US7744896B1 (en)	2010-06-29
DK1035865T3 (da)	2008-02-04

Publication	Publication Date	Title
US7744896B1 (en)	2010-06-29	HIV-1 Tat compositions
Lu et al.	1996	Simian immunodeficiency virus DNA vaccine trial in macaques
Paliard et al.	2000	Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques
EP0882134B1 (fr)	2009-04-22	Procedes et compositions pour l'immunisation genetique protectrice et therapeutique
Cafaro et al.	2000	SHIV89. 6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine
Heeney et al.	1999	HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates
JP4418101B2 (ja)	2010-02-17	遺伝子ワクチンのための弱毒化ｖｉｆＤＮＡ免疫化カセット
Leung et al.	2000	The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins
Agadjanyan et al.	1997	An HIV type 2 DNA vaccine induces cross-reactive immune responses against HIV type 2 and SIV
Girard et al.	1997	Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus
Mahdavi et al.	2010	HIV-1 Gag p24-Nef fusion peptide induces cellular and humoral immune response in a mouse model
RU2232815C2 (ru)	2004-07-20	Самореплицирующийся рекомбинантный вектор, экспрессирующий регуляторные белки вич, способ его получения, вакцина для иммунизации против вич на основе днк, содержащая указанный вектор, способ лечения или профилактики вич
Kumar et al.	2001	Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency virus (SHIV89. 6P)
Mossman et al.	2004	Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles
US20010004531A1 (en)	2001-06-21	AIDS DNA vaccine that prevents SIVmac239 virus infection in monkeys
Maggiorella et al.	2007	Multiprotein genetic vaccine in the SIV‐Macaca animal model: a promising approach to generate sterilizing immunity to HIV infection
Calarota et al.	2004	Approaches for the design and evaluation of HIV-1 DNA vaccines
WAKRIM et al.	1996	Superinfection of HIV-2-preinfected macaques after rectal exposure to a primary isolate of SIVmac251
Vasan et al.	2007	T cell immune responses to HIV-1
Lucas et al.	2016	Dendritic cells primed with a chimeric plasmid containing HIV‐1‐gag associated with lysosomal‐associated protein‐1 (LAMP/gag) is a potential therapeutic vaccine against HIV
Foutsa et al.	2015	Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection
MXPA00005325A (en)	2001-12-13	Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination
Hirao	2010	Enhancement of immune responses to DNA vaccines
Baumeister et al.	2002	Prospects for an HIV vaccine: Conventional approaches and DNA immunization
Boyer et al.	2003	Engineering DNA vaccination as an approach to HIV immune therapy

OA11419A - HIV-1tat, or derivatives thereof for prophylactic and therapeutic vaccination. - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (1)

Publications (1)

Family

ID=11405378

Family Applications (1)

Country Status (23)

Cited By (1)

Families Citing this family (38)

Family Cites Families (10)

Cited By (1)

Also Published As

Similar Documents